It is known that ER+ERB2- RANK-overexpressing BC cells have a staminal and mesenchymal phenotype, with a decreased proliferation rate and decreased susceptibility to chemotherapy and hormone therapy (HT). The gene discussed is TNFRSF11A; the disease is breast cancer.